Over the past three years, the NSE Pharma Index has fallen 30% even as the benchmark Nifty rose 18%
Firstsource CEO Rajesh Subramaniam offloads shares worth Rs.17 crore in FY19 so far
Promoter’s market purchase fails to arrest slide in Manpasand Beverages
Dr Reddy’s promoter GV Prasad buys in the open market amid growing headwind
Manpasand Beverages’ dream run is being questioned as the auditor’s untimely exit raises a red flag
Dairy companies are growing by venturing beyond their home market and launching value-added products
The worst seems to be behind for Sun Pharma as its Halol plant seems set for clearance and its specialty portfolio tests water in the US
The government's thrust on substituting gas in place of crude-based fuel makes gas-infrastructure providers good stocks to buy
Laurus Labs is crucially poised, as investors look forward to its R&D efforts finally paying off
Ambit Capital’s head of research, Nitin Bhasin, on what separates a handful of Indian companies from the also-ran
Jaguar Growth Partners' Gary Garrabrant on the opportunities in the Indian real estate sector
Richard Iley, chief economist, emerging markets, BNP Paribas, talks about the prospects for the Indian market
Jim Rogers on why China remains a better investment bet despite the slowdown
In the final part, Raamdeo Agrawal stresses on zero distraction when digging deeper to find great opportunities
In the first of a two-part interview, Raamdeo Agrawal points out the drawback of the 100X study and the attributes of extraordinary growth
